Want to see PTHS full AI Analyst Report?
PTHS Stock Chart & Stats
$25.92
$1.67(6.44%)
At close: 4:00 PM EDT
$25.92
$1.67(6.44%)
Day’s Range― - ―
52-Week Range$16.50 - $37.50
Previous Close$27.59
Volume91.43K
Average Volume (3M)30.94K
Market Cap
$99.61M
Enterprise Value$90.28
Total Cash (Recent Filing)$32.23M
Total Debt (Recent Filing)$52.93M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 13, 2026EPS Estimate
-2.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-40.69
Shares Outstanding3,475,645
10 Day Avg. Volume22,109
30 Day Avg. Volume30,941
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.50
Price to Sales (P/S)3.47
P/FCF Ratio-2.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$61.20Price Target Upside136.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-10.35
Revenue Forecast (FY)$63.77M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Strong Gross MarginsRapidly rising revenue alongside a durable ~63% gross margin indicates attractive product economics. As volume grows, high gross margins provide structural leverage to absorb commercial spend and improve operating profitability over months as launches and inventory normalization progress.
Commercial Launch Traction And Prescriber GrowthSustained, double-digit prescription and revenue growth shows reproducible demand and early commercial productivity. Expanding prescriber base and accelerating weekly/monthly dispensing signal durable adoption that can compound as the salesforce matures and repeat use accrues.
Payer Access And PBM Win Supporting UptakeBroad payer coverage and a material PBM contract materially reduce access friction and patient out‑of‑pocket barriers. Structural payer support improves convertibility of prescriptions to dispensations and underpins sustainable demand and revenue growth over the medium term.
Bears Say
Ongoing Free Cash Flow BurnPersistent negative operating cash flow and free cash flow indicate reliance on external financing to fund operations. This structural cash burn elevates refinancing and dilution risk and constrains strategic flexibility until commercial margins and operating leverage materially improve.
Deep Net Losses And Negative EBITDALarge ongoing losses and negative adjusted EBITDA reflect a cost base that outpaces current revenue. Without sustained margin expansion or material scale benefits, the company must continue financing operations, pressuring returns and making profitability timing uncertain over the coming quarters.
Gross‑to‑net Pressure Reducing Realized RevenueAn expected structural increase in gross‑to‑net deductions to the mid‑30% range lowers net revenue per unit and compresses long‑term margin potential. Higher GTN requires either higher volume, pricing adjustments, or cost reductions to preserve durable profitability.
Pelthos Therapeutics News
PTHS FAQ
What was Pelthos Therapeutics’s price range in the past 12 months?
Pelthos Therapeutics lowest stock price was $16.50 and its highest was $37.50 in the past 12 months.
What is Pelthos Therapeutics’s market cap?
Pelthos Therapeutics’s market cap is $99.61M.
When is Pelthos Therapeutics’s upcoming earnings report date?
Pelthos Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 8 days.
How were Pelthos Therapeutics’s earnings last quarter?
Pelthos Therapeutics released its earnings results on May 14, 2026. The company reported -$3.09 earnings per share for the quarter, beating the consensus estimate of -$3.45 by $0.36.
Is Pelthos Therapeutics overvalued?
According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued.
Does Pelthos Therapeutics pay dividends?
Pelthos Therapeutics does not currently pay dividends.
What is Pelthos Therapeutics’s EPS estimate?
Pelthos Therapeutics’s EPS estimate is -2.82.
How many shares outstanding does Pelthos Therapeutics have?
Pelthos Therapeutics has 3,475,645 shares outstanding.
What happened to Pelthos Therapeutics’s price movement after its last earnings report?
Pelthos Therapeutics reported an EPS of -$3.09 in its last earnings report, beating expectations of -$3.45. Following the earnings report the stock price went up 6.459%.
Which hedge fund is a major shareholder of Pelthos Therapeutics?
Currently, no hedge funds are holding shares in PTHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pelthos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.20 (136.11% Upside)
$61.20 (136.11% Upside)
Blogger Sentiment
Bullish
PTHS Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 201.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $959.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Company Description
Pelthos Therapeutics
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
PTHS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive commercialization story: strong prescription growth (25% QoQ), 17% revenue growth QoQ, expanding prescriber base and payer access, successful PBM engagement, and improved liquidity from a debt draw. These operational and commercial wins are tempered by ongoing unprofitable quarterly results, negative adjusted EBITDA, rising SG&A and interest costs, anticipated higher gross-to-net pressures (mid-30s), and some inventory accounting timing effects. On balance, the company shows solid early launch traction and strengthened financial flexibility while still investing heavily toward profitability and additional product launches.View all PTHS earnings summariesPTHS Stock 12 Month Forecast
Average Price Target
$61.20
▲(136.11% Upside)
Technical Analysis
Immunic
―
Fortress Biotech
―
Verrica Pharmaceuticals
―
Instil Bio
―
Tevogen Bio Holdings
―